Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01177683
Title Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sherif Farag, MB, BS
Indications

multiple myeloma

Therapies

Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin

Filgrastim

Age Groups: adult
Covered Countries USA


No variant requirements are available.